FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2080385145> ?p ?o ?g. }

• W2080385145 abstract "Background: Poly (ADP-ribose) polymerase (PARP) is an enzyme involved in DNA repair. PARP inhibitors operate on the principle of synthetic lethality in conjunction with DNA damaging agents, and are likely to be useful for treatment of BRCA-mutated cancers and triple negative breast cancers exhibiting ‘BRCA-ness’ or other signs of DNA repair deficiency. Multiple PARP inhibitors have been developed, such as Olaparib (AstraZeneca), BSI-201 (Sanofi-Aventis) and ABT-888 (Abbott Laboratories). Though some clinical trials have shown drugs in this class to be promising, not all results have been positive. As PARP inhibitors differ in mechanism of action, dosing interval and toxicities, trial results seem to depend on the specific combination of PARP inhibitor and patient population. To understand why some studies succeeded and others failed and to guide new clinical trials in patient selection, there is an urgent need for biomarker identification, both for PARP inhibitors in general and for the specific idiosyncratic mechanisms of each drug. Material and Methods: Thirty-three in vitro breast cancer cell lines were administered the PARP inhibitor Olaparib, with sensitivity to the compound summarized as the dose necessary to kill 50% of each culture. mRNA expression (Affymetrix U133A, Exon 1.0ST array) and transcriptome sequence (Illumina GAII) were available for 22/33 cell lines, among which 9 were sensitive and 13 resistant. To obtain robust predictive markers that are minimally dependent on the specific PARP inhibitor and expression platform, a bottom-up approach was opted for, restricted to genes in the major DNA repair pathways. Logistic regression with forward selection was used to determine the most important markers, further reduced based on consistency across platforms. The weighted voting algorithm was used to build the final predictor. Eight U133A data sets with number of tumor samples varying from 61 to 289 were subsequently used to verify prevalence and to identify the subpopulations that are likely to respond according to the predictor. To verify cross-platform generalizability, the signature was additionally tested in 430 TCGA samples with custom Agilent 244K gene expression. Results: For the development of a genomic signature that might work for multiple PARP inhibitors and expression platforms, prior knowledge of DNA repair pathways was incorporated and stringent criteria for marker inclusion were applied using three different platforms. Eight genes fulfilled the criteria, of which 5 were resistance markers and 3 sensitivity markers. When testing the 8-gene signature in eight U133A data sets, 40–48% of patients were predicted to be responsive to Olaparib. In addition, well-known markers (ER, PR, ERBB2, KRT5/17) were examined in patients expressing the 8-gene sensitivity signature. A higher percentage of these patients were ERBB2-negative and did overexpress KRT5/17, indicative for the basal subtype. Prevalence and relationship with these markers were confirmed in 430 samples on a distinct platform (Agilent). Conclusion: Cell line exposure to Olaparib has yielded an 8-gene predictor of sensitivity. This signature was observed in a substantial fraction of primary breast tumors predicted to benefit from Olaparib. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P1-06-22." @default.
• W2080385145 created "2016-06-24" @default.
• W2080385145 creator A5014225184 @default.
• W2080385145 creator A5014555999 @default.
• W2080385145 creator A5016497396 @default.
• W2080385145 creator A5022839853 @default.
• W2080385145 creator A5036890758 @default.
• W2080385145 creator A5040239021 @default.
• W2080385145 creator A5040450413 @default.
• W2080385145 creator A5058302052 @default.
• W2080385145 creator A5058973407 @default.
• W2080385145 creator A5068129695 @default.
• W2080385145 creator A5073168417 @default.
• W2080385145 creator A5076367516 @default.
• W2080385145 creator A5089371260 @default.
• W2080385145 creator A5091194544 @default.
• W2080385145 date "2011-12-15" @default.
• W2080385145 modified "2023-10-17" @default.
• W2080385145 title "P1-06-22: Identification of Biomarkers in Breast Cancer for Prediction of Response to PARP Inhibitor Olaparib." @default.
• W2080385145 doi "https://doi.org/10.1158/0008-5472.sabcs11-p1-06-22" @default.
• W2080385145 hasPublicationYear "2011" @default.
• W2080385145 type Work @default.
• W2080385145 sameAs 2080385145 @default.
• W2080385145 citedByCount "0" @default.
• W2080385145 crossrefType "proceedings-article" @default.
• W2080385145 hasAuthorship W2080385145A5014225184 @default.
• W2080385145 hasAuthorship W2080385145A5014555999 @default.
• W2080385145 hasAuthorship W2080385145A5016497396 @default.
• W2080385145 hasAuthorship W2080385145A5022839853 @default.
• W2080385145 hasAuthorship W2080385145A5036890758 @default.
• W2080385145 hasAuthorship W2080385145A5040239021 @default.
• W2080385145 hasAuthorship W2080385145A5040450413 @default.
• W2080385145 hasAuthorship W2080385145A5058302052 @default.
• W2080385145 hasAuthorship W2080385145A5058973407 @default.
• W2080385145 hasAuthorship W2080385145A5068129695 @default.
• W2080385145 hasAuthorship W2080385145A5073168417 @default.
• W2080385145 hasAuthorship W2080385145A5076367516 @default.
• W2080385145 hasAuthorship W2080385145A5089371260 @default.
• W2080385145 hasAuthorship W2080385145A5091194544 @default.
• W2080385145 hasConcept C121608353 @default.
• W2080385145 hasConcept C126322002 @default.
• W2080385145 hasConcept C134935766 @default.
• W2080385145 hasConcept C182979987 @default.
• W2080385145 hasConcept C2778502085 @default.
• W2080385145 hasConcept C2779138821 @default.
• W2080385145 hasConcept C2779962180 @default.
• W2080385145 hasConcept C2781197716 @default.
• W2080385145 hasConcept C2908647359 @default.
• W2080385145 hasConcept C502942594 @default.
• W2080385145 hasConcept C530470458 @default.
• W2080385145 hasConcept C54355233 @default.
• W2080385145 hasConcept C552990157 @default.
• W2080385145 hasConcept C71924100 @default.
• W2080385145 hasConcept C82381507 @default.
• W2080385145 hasConcept C86803240 @default.
• W2080385145 hasConcept C99454951 @default.
• W2080385145 hasConceptScore W2080385145C121608353 @default.
• W2080385145 hasConceptScore W2080385145C126322002 @default.
• W2080385145 hasConceptScore W2080385145C134935766 @default.
• W2080385145 hasConceptScore W2080385145C182979987 @default.
• W2080385145 hasConceptScore W2080385145C2778502085 @default.
• W2080385145 hasConceptScore W2080385145C2779138821 @default.
• W2080385145 hasConceptScore W2080385145C2779962180 @default.
• W2080385145 hasConceptScore W2080385145C2781197716 @default.
• W2080385145 hasConceptScore W2080385145C2908647359 @default.
• W2080385145 hasConceptScore W2080385145C502942594 @default.
• W2080385145 hasConceptScore W2080385145C530470458 @default.
• W2080385145 hasConceptScore W2080385145C54355233 @default.
• W2080385145 hasConceptScore W2080385145C552990157 @default.
• W2080385145 hasConceptScore W2080385145C71924100 @default.
• W2080385145 hasConceptScore W2080385145C82381507 @default.
• W2080385145 hasConceptScore W2080385145C86803240 @default.
• W2080385145 hasConceptScore W2080385145C99454951 @default.
• W2080385145 hasLocation W20803851451 @default.
• W2080385145 hasOpenAccess W2080385145 @default.
• W2080385145 hasPrimaryLocation W20803851451 @default.
• W2080385145 hasRelatedWork W1487847005 @default.
• W2080385145 hasRelatedWork W1867851354 @default.
• W2080385145 hasRelatedWork W1973736220 @default.
• W2080385145 hasRelatedWork W2003876107 @default.
• W2080385145 hasRelatedWork W2044433723 @default.
• W2080385145 hasRelatedWork W2062510022 @default.
• W2080385145 hasRelatedWork W2105336633 @default.
• W2080385145 hasRelatedWork W2107264032 @default.
• W2080385145 hasRelatedWork W2144150278 @default.
• W2080385145 hasRelatedWork W2235738090 @default.
• W2080385145 hasRelatedWork W2315120232 @default.
• W2080385145 hasRelatedWork W2321313460 @default.
• W2080385145 hasRelatedWork W2598708956 @default.
• W2080385145 hasRelatedWork W2621737279 @default.
• W2080385145 hasRelatedWork W2740568928 @default.
• W2080385145 hasRelatedWork W2810343615 @default.
• W2080385145 hasRelatedWork W2912298595 @default.
• W2080385145 hasRelatedWork W2944140472 @default.
• W2080385145 hasRelatedWork W3131099971 @default.
• W2080385145 hasRelatedWork W3183136313 @default.
• W2080385145 isParatext "false" @default.
• W2080385145 isRetracted "false" @default.
• W2080385145 magId "2080385145" @default.
• W2080385145 workType "article" @default.